Sodium Oxybate
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Sodium Oxybate: From Narcolepsy with Cataplexy to Insomnia
One-Sentence Summary
Sodium oxybate (brand name Xyrem) is a CNS depressant originally developed and approved internationally for narcolepsy with cataplexy. The TxGNN model predicts it may also be effective for Insomnia, with 13 clinical trials and 13 publications currently supporting this direction — including a completed, placebo-controlled Phase 2 trial specifically in chronic insomnia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy with cataplexy (per international approvals cited in trial/literature records; not currently licensed in Norway) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action data is not populated in the drug record (marked as a data gap). However, information embedded in the trial and literature records itself indicates that sodium oxybate acts as a GABA-B and GHB receptor agonist, promoting slow-wave (deep) sleep and improving sleep consolidation — this is stated explicitly in several of the underlying study summaries (e.g., PMID 21476957: "GABA(B) receptor agonists have reported effects on sleep including decreased sleep onset latency, increased sleep consolidation and increases in slow wave sleep").
Sodium oxybate's approved indication, narcolepsy with cataplexy, is itself a sleep-architecture disorder in which the drug's core benefit is consolidating fragmented, disrupted nighttime sleep. Insomnia is mechanistically adjacent — both conditions involve impaired sleep initiation/maintenance and reduced slow-wave sleep. This overlap is why a completed, placebo-controlled Phase 2 trial (NCT00383643) directly tested sodium oxybate against zolpidem (Ambien) in chronic insomnia patients, independent of narcolepsy.
That said, sodium oxybate is also GHB, a compound with recognized abuse liability, dependence potential, and CNS/respiratory depression risk (reflected indirectly in the literature evidence, e.g., PMID 11174231 on GHB withdrawal syndrome). This raises the bar for how a repurposing signal in a benign condition like insomnia should be evaluated relative to a serious, refractory condition like narcolepsy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00383643 | Phase 2 | Completed | 48 | Randomized, double-blind, double-dummy, placebo-controlled trial comparing sodium oxybate and zolpidem in chronic insomnia |
| NCT02637648 | Phase 3 | Unknown | 60 | Sodium oxybate (3–9g/night) for headache response, sleep quality and QoL in cluster headache with sleep disturbance |
| NCT00641186 | Phase 2 | Completed | 30 | Open-label trial of Xyrem for excessive daytime sleepiness and nocturnal sleep disturbance in Parkinson's disease |
| NCT04803786 | N/A | Completed | 110 | Real-world observational study (TENOR) on patients switching from Xyrem to low-sodium oxybate |
| NCT04508166 | N/A | Completed | 27 | Deep-sleep-boosting drug conditions (incl. sodium oxybate) tested for preventing post-traumatic intrusive memories |
| NCT00594256 | Phase 2 | Completed | 8 | Open-label pilot of adjunctive Xyrem for schizophrenia and associated sleep disturbances |
| NCT00330291 | Phase 2 | Withdrawn | 0 | Planned trial of Xyrem for treatment-refractory insomnia due to PTSD |
| NCT07077278 | Phase 4 | Not yet recruiting | 25 | Low-sodium oxybate for autonomic symptom burden in idiopathic hypersomnia with POTS |
| NCT06421532 | Phase 2 | Enrolling by invitation | 60 | Low-sodium oxybate ± vagus nerve stimulation to enhance glymphatic clearance via deepened sleep in CAA |
| NCT03626727 | Early Phase 1 | Withdrawn | 0 | Planned open-label trial of Xyrem for post-traumatic narcolepsy and hypersomnia |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26171909 | 2015 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Effects of opioid, hypnotic and sedating medications, including GABA-B agonists, on sleep-disordered breathing |
| 36931805 | 2023 | RCT | Lancet Neurology | Double-blind, placebo-controlled trial context for narcolepsy sleep-wake pharmacotherapy in pediatric patients |
| 40120323 | 2025 | Cohort study (propensity-matched) | J Clin Neurosci | Treatment patterns and comorbidities of narcolepsy patients treated with immediate-release sodium oxybate |
| 18852348 | 2008 | Open-label study | Arch Neurol | Sodium oxybate improved polysomnographic sleep measures and daytime sleepiness in Parkinson's disease |
| 37590830 | 2023 | Review | Continuum (Minneap Minn) | Comprehensive review of pediatric sleep disorders including insomnia and narcolepsy |
| 18805301 | 2008 | Review | Revue Neurologique | Overview of narcolepsy with cataplexy including sleep-maintenance insomnia as a feature |
| 20082966 | 2009 | Review | Parkinsonism Relat Disord | Sleepiness and sleep disruption in Parkinson's disease |
| 20166851 | 2010 | Review | Expert Opin Emerg Drugs | Emerging pharmacologic treatments for narcolepsy and nocturnal sleep disruption |
| 21815499 | 2011 | Review | Revue Medicale Suisse | Bidirectional relationship between chronic pain and sleep disorder, treatment approaches |
| 31526967 | 2019 | Case report | Sleep Medicine | Sodium oxybate used to treat severe sleep initiation failure in a child with EBV encephalitis |
Norway Market Information
Currently not marketed in Norway; no marketing authorizations are on record.
Safety Considerations
Please refer to the package insert for safety information. (Note: TFDA/local label warnings, contraindications, and drug-drug interaction data are currently a blocking data gap — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: A completed, placebo-controlled Phase 2 trial (NCT00383643) directly supports efficacy in chronic insomnia, giving this candidate an L2 evidence level. However, sodium oxybate is not currently marketed in Norway, and formal safety label data (warnings, contraindications) is a blocking data gap — this is required before any safety pre-assessment (S1) can proceed, and is particularly important given sodium oxybate's known CNS depressant and controlled-substance profile.
To proceed, the following is needed:
- TFDA/local package insert data (warnings, contraindications) — currently blocking
- Formal DrugBank-sourced mechanism of action confirmation
- Drug-drug interaction data (current query returned no results)
- Assessment of abuse/dependence risk relative to a non-life-threatening indication (insomnia) versus the original refractory indication (narcolepsy with cataplexy)
- Regulatory pathway review, since the drug currently holds no Norwegian marketing authorization
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.